Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapy

This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Novartis acquired the gene therapy specialist AveXis in April last year and Zolgensma had been subsequently developed by them. ... There had already been concerns over how commercially sustainable the field of cell and gene therapy is, with Zolgensma’s

Latest news

  • NICE unveils long-awaited review of methodologies NICE unveils long-awaited review of methodologies

    He added: “NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and ... gene therapy, mean products are becoming ever

  • FDA will maintain the pace, vows Woodcock, but warns of skills gap FDA will maintain the pace, vows Woodcock, but warns of skills gap

    a potential flood of new cell and gene therapy products. ... Also eyecatching were Woodcock’s comments on two high profile FDA approvals of spinal muscular atrophy (SMA) treatments, Biogen’s Spinraza and Novartis’ gene therapy Zolgensma.

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    European real world evidence (RWE) frameworks, in order to nurture the nascent cell and gene therapy revolution in the region. ... Investment has been flooding into the cell and gene therapy pipeline in that same period, despite the fact that the

  • Amicus forms gene therapy manufacturing partnership with Catalent Amicus forms gene therapy manufacturing partnership with Catalent

    Biotech invests to speed gene therapies into clinical trials. US biotech Amicus Therapeutics is to work with drug development services company Catalent Biologics to develop its cell and gene therapy manufacturing ... it has added the gene therapy

  • Syncona start-up Quell Therapeutics appoints chief exec Syncona start-up Quell Therapeutics appoints chief exec

    Syncona is on a roll at present, having launched a string of new cell and gene therapy-focused companies in the last few years. ... He has 25 years’ experience in the industry, including solid organ and cell transplantation therapy areas.

More from news
Approximately 41 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... Eye diseases are at the forefront of the

  • Gene therapy market access Q&A Gene therapy market access Q&A

    Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients. ... Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    All this points to a revolution brought about by cell and gene therapy, not just in clinical care, but also in the pricing and reimbursement framework to support it. ... He’s seen a rapid change in attitudes towards healthcare systems in the last 12

  • Cell and gene therapy Cell and gene therapy

    Lonza has worked with 150 cell and gene therapy developers and each project has required a different approach, Hong added. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said Hong.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Novartis has a deal with Spark to market Luxturna in Europe,

More from intelligence
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

    the cost curve to accommodate new and expensive cell and gene therapies.  In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.

  • Event: World Pharma Pricing and Market Access Congress

    Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March. ... A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding

  • OPEN Health

    Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era. ... OPEN Health Medical Communications announces Group MD promotions and welcomes new Creative Director.

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Random42 produce over 200 individual digital projects each year and have won over 175 industry awards in their 26-year

  • Training the next generation of biotech leaders

    As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy. ... It brings engineers and people from the life sciences sector into the department to learn about biochemical engineering

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics